Supernus Pharmaceuticals (SUPN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $44.00 price target.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stacy Ku’s rating is based on several factors that highlight the potential growth and strategic positioning of Supernus Pharmaceuticals. The company reported a first-quarter revenue of approximately $149.8 million, which was slightly above consensus expectations. Despite a quarterly decline, the management’s guidance for 2025 indicates a revenue range of $600-630 million, showcasing a promising growth trajectory excluding the impact of Trokendi and Oxtellar.
A significant factor in the Buy rating is the performance and future potential of Qelbree, a key product for Supernus. Although Qelbree’s first-quarter sales were slightly below expectations, the management anticipates improvements in the upcoming quarters. The product’s unique mechanism of action and positive clinician feedback suggest a strong market potential, particularly in the adult ADHD segment. The expectation that Qelbree could capture a significant share of the ADHD market further supports the optimistic outlook for Supernus Pharmaceuticals.